Simulations Plus Promotes John DiBella To Vice President Of Marketing And Sales

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced the promotion of Mr. John DiBella to the position of Vice President of Marketing and Sales.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “Since John took over marketing and sales in 2009, we’ve seen accelerated growth compared to the years prior, performance which made him deserving of this promotion. As an officer, John will now have signature authority on corporate documents, including software license agreements, confidentiality agreements, and consulting and collaboration contracts. We look forward to John’s continued excellent performance in his expanded role.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Copyright Business Wire 2010

If you liked this article you might like

Market Can't Sustain Upside Push

10 High-Growth Health Care Stocks to Buy Now

Mid-Cap A+ Rated Stocks That Pay High Dividends

12 'A+' Rated Stocks With Great Growth Potential and High Return on Invested Capital

20 A+ Rated Mid-Cap Growth Stocks